Berkshire's UnitedHealth Bet Highlights Long-Term Confidence Despite Depressed Earnings

Bank of America Securities has raised its UnitedHealth Group (UNH) price target to $325, projecting an earnings rebound by 2027, driven by expected Medicare Advantage (MA) rate updates and Star Ratings, despite potential offsetting coding adjustments. This bullish outlook aligns with recent significant investments from high-profile investors like Warren Buffett and Michael Burry, signaling confidence in UNH's competitive positioning and a broader sector turnaround, even as current earnings remain depressed. The company's ability to deliver consistent performance and favorable MA policy will be critical for restoring investor confidence and realizing the projected upside.

Analysis

UnitedHealth Group (UNH) is signaling a potential long-term recovery, underscored by Bank of America's price target increase to $325 and a forecast for an earnings rebound by 2027, despite a maintained Neutral rating. This cautiously optimistic outlook is reinforced by significant new positions from high-profile investors, including Berkshire Hathaway's purchase of over 5 million shares and Michael Burry's acquisition of call contracts on 350,000 shares, suggesting a strategic bet on a sector turnaround. The investment thesis hinges critically on the performance of its Medicare Advantage (MA) business, with profitability dependent on two key upcoming events: the 2027 Star Ratings release in mid-October, which determines eligibility for a crucial 5% quality bonus in a segment with thin 3-5% margins, and the 2027 MA rate update due in February 2026. While the 2026 rate update was the strongest in a decade, a significant risk remains for 2027, as a new coding adjustment (V29) could offset potential gains. The stock's performance is contingent on management's ability to deliver consistent earnings beats and improve its medical loss ratio, as BofA notes it has been over two years since a strong 'United-type' quarter.

Key Decisions for Investors

• Investors with a long-term horizon may consider the current depressed earnings as an entry point, aligning with the bullish positioning of notable investors like Warren Buffett and Michael Burry who are betting on a multi-year recovery.
• Closely monitor two critical regulatory catalysts: the CMS 2027 Star Ratings release in mid-October, and the 2027 Medicare Advantage rate update in February 2026, as these will directly impact margin recovery and profitability.
• Scrutinize upcoming quarterly results for evidence of improved execution, specifically focusing on the company's ability to control its medical loss ratio and deliver consistent earnings beats to restore investor confidence.